Current treatment protocols for high-risk neuroblastoma include high-dose chemotherapy, surgery, stem cell transplantation and radiation. Recently, dinutuximab, a chimeric monoclonal antibody, specifically targeting the disialoganglioside highly expressed on neuroblastoma cells, has been licensed. Its incorporation in maintenance therapy represents a promising treatment approach. The introduction of its use was a challenge for the entire multidisciplinary team in our pediatric hematology and oncology ward just as for the pharmacy team. An overview of the key points that were observed is presented.
TriggRTurnerS.ALK in neuroblastoma: biological and therapeutic indications. Cancers2018;
10: 113
2.
SaitSModakS.Anti-GD2 immunotherapy for neuroblastoma.Exp Rev Anticancer Ther2017;
17: 889–904.
3.
PastorERMousaSA.Current management of neuroblastoma and future direction.Crit Rev Oncol Hematol2019;
138: 38–a43.
4.
KholodenkoIVKalinovskyDVDoroninII, et al.
Neuroblastoma origin and therapeutic targets for immunotherapy.J Immunol Res2018;
2018: 7394268.
5.
SwiftCCEklundMJKravekaJM, et al.
Updates in diagnosis, management, and treatment of neuroblastoma.Radiographics2018;
38: 566–580.
6.
LadensteinRPötschgerUValteau-CouanetD, et al.
Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1).Cancers2020;
12: 309.
7.
WhittleSBSmithVDohertyE, et al.
Overview and recent advances in the treatment of neuroblastoma. Exp Rev Anticancer Ther2017;
17: 369–386.
8.
ZagePE.Novel therapies for relapsed and refractory neuroblastoma. Children2018;
5: pii: E148.
9.
GreenwoodKLFosterJH.The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.Expert Opin Drug Saf2018;
17: 1257–1262.
MorenoLMorozVOwensC, et al.
Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): results of the BEACON-Neuroblastoma randomized phase 2 trial – a European Innovative Therapies for Children with Cancer (ITCC) – International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. J Clin Oncol2019;
37: 10001–10001.
12.
OliverG.Optimising patient safety when using elastomeric pumps to administer outpatient parenteral antibiotic therapy.Br J Nurs2016;
25: S22–S27.
